hiv

Summary

Summary: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.

Top Publications

  1. ncbi Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
    Robert M Grant
    J David Gladstone Institutes, University of California at San Francisco, 1650 Owens St, San Francisco, CA 94158, USA
    N Engl J Med 363:2587-99. 2010
  2. ncbi HIV infection and multidrug-resistant tuberculosis: the perfect storm
    Charles D Wells
    Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Infect Dis 196:S86-107. 2007
  3. ncbi Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    N Engl J Med 354:251-60. 2006
  4. ncbi Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial
    Shabbar Jaffar
    Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
    Lancet 374:2080-9. 2009
  5. ncbi Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr?
    Diana Ayinde
    Institut Cochin, Universite Paris Descartes, CNRS UMR 8104, Paris, France
    Retrovirology 7:35. 2010
  6. ncbi Episodic sexual transmission of HIV revealed by molecular phylodynamics
    Fraser Lewis
    Institute of Evolutionary Biology, School of Biological Sciences, University of Edinburgh, Edinburgh, Scotland
    PLoS Med 5:e50. 2008
  7. ncbi HIV rebounds from latently infected cells, rather than from continuing low-level replication
    Beda Joos
    Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 105:16725-30. 2008
  8. ncbi Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire
    Sue J Goldie
    Department of Health Policy and Management, Program in Health Decision Science, Harvard School of Public Health, Boston, MA 02115, USA
    N Engl J Med 355:1141-53. 2006
  9. ncbi The molecular basis of HIV capsid assembly--five years of progress
    Catherine S Adamson
    School of Animal and Microbial Sciences, The University of Reading, Reading RG6 6AJ, UK
    Rev Med Virol 14:107-21. 2004
  10. ncbi Effect of herpes simplex suppression on incidence of HIV among women in Tanzania
    Deborah Watson-Jones
    London School of Hygiene and Tropical Medicine, London
    N Engl J Med 358:1560-71. 2008

Research Grants

  1. Relationship of metabolic abnormalities to hepatic steatosis in HIV
    Richard Sterling; Fiscal Year: 2007
  2. Role of the OPI1 gene in controlling viability of Candida glabrata
    TODD REYNOLDS; Fiscal Year: 2007
  3. Vaccination against mucosal HIV clade C transmission
    Ruth Ruprecht; Fiscal Year: 2007
  4. Evaluation of RNA transport elements in HIV-1 vectors
    SRINIVAS KUMAR; Fiscal Year: 2007
  5. Infant immunoprophylaxis against a primate lentivirus
    Ruth Ruprecht; Fiscal Year: 2007
  6. International HIV-associated Opportunistic Pneumonias (IHOP) Study
    Laurence Huang; Fiscal Year: 2009
  7. International HIV-associated Opportunistic Pneumonias (IHOP) Study
    Laurence Huang; Fiscal Year: 2009
  8. Genome Integrity in Candida albicans
    Judith G Berman; Fiscal Year: 2010
  9. Haemophilus ducreyi Resistance to Antimicrobial Peptides
    MARGARET BAUER; Fiscal Year: 2007
  10. MUCOSAL DEFENSE MECHANISMS IN SUBSTANCE ABUSE
    David Brown; Fiscal Year: 2009

Detail Information

Publications250 found, 100 shown here

  1. ncbi Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
    Robert M Grant
    J David Gladstone Institutes, University of California at San Francisco, 1650 Owens St, San Francisco, CA 94158, USA
    N Engl J Med 363:2587-99. 2010
    Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition.
  2. ncbi HIV infection and multidrug-resistant tuberculosis: the perfect storm
    Charles D Wells
    Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Infect Dis 196:S86-107. 2007
    ..The global human immunodeficiency virus (HIV) infection epidemic has caused explosive increases in TB incidence and may be contributing to increases in MDR-TB ..
  3. ncbi Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    N Engl J Med 354:251-60. 2006
    Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which patients can easily adhere.
  4. ncbi Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial
    Shabbar Jaffar
    Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
    Lancet 374:2080-9. 2009
    Identification of new ways to increase access to antiretroviral therapy in Africa is an urgent priority. We assessed whether home-based HIV care was as effective as was facility-based care.
  5. ncbi Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr?
    Diana Ayinde
    Institut Cochin, Universite Paris Descartes, CNRS UMR 8104, Paris, France
    Retrovirology 7:35. 2010
    b>HIV viruses encode a set of accessory proteins, which are important determinants of virulence due to their ability to manipulate the host cell physiology for the benefit of the virus...
  6. ncbi Episodic sexual transmission of HIV revealed by molecular phylodynamics
    Fraser Lewis
    Institute of Evolutionary Biology, School of Biological Sciences, University of Edinburgh, Edinburgh, Scotland
    PLoS Med 5:e50. 2008
    ..For HIV, the long period of infectivity has made the interpretation of contact networks more difficult, and major ..
  7. ncbi HIV rebounds from latently infected cells, rather than from continuing low-level replication
    Beda Joos
    Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 105:16725-30. 2008
    ..To further characterize rebounding virus, we performed extensive longitudinal clonal evolutionary studies of HIV env C2-V3-C3 regions and exploited the temporal relationships of rebounding plasma viruses with regard to ..
  8. ncbi Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire
    Sue J Goldie
    Department of Health Policy and Management, Program in Health Decision Science, Harvard School of Public Health, Boston, MA 02115, USA
    N Engl J Med 355:1141-53. 2006
    ..As antiretroviral therapy is increasingly used in settings with limited resources, key questions about the timing of treatment and use of diagnostic tests to guide clinical decisions must be addressed...
  9. ncbi The molecular basis of HIV capsid assembly--five years of progress
    Catherine S Adamson
    School of Animal and Microbial Sciences, The University of Reading, Reading RG6 6AJ, UK
    Rev Med Virol 14:107-21. 2004
    The assembly of HIV is relatively poorly investigated when compared with the process of virus entry...
  10. ncbi Effect of herpes simplex suppression on incidence of HIV among women in Tanzania
    Deborah Watson-Jones
    London School of Hygiene and Tropical Medicine, London
    N Engl J Med 358:1560-71. 2008
    ..simplex virus type 2 (HSV-2) is associated with an increased risk of acquiring infection with the human immunodeficiency virus (HIV). This study tested the hypothesis that HSV-2 suppressive therapy reduces the risk of HIV acquisition.
  11. ncbi Evidence for direct involvement of the capsid protein in HIV infection of nondividing cells
    Masahiro Yamashita
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    PLoS Pathog 3:1502-10. 2007
    b>HIV and other lentiviruses can productively infect nondividing cells, whereas most other retroviruses, such as murine leukemia virus, require cell division for efficient infection...
  12. ncbi Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings
    Rami Kantor
    Division of Infectious Diseases, Brown University, Providence, Rhode Island, USA
    Clin Infect Dis 49:454-62. 2009
    The monitoring of patients with human immunodeficiency virus (HIV) infection who are treated with antiretroviral medications in resource-limited settings is typically performed by use of clinical and immunological criteria...
  13. ncbi Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection
    Carolina Garrido
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 65:320-6. 2010
    Little is known about the extent and predictors of polymorphisms potentially influencing the susceptibility to HIV integrase inhibitors (INIs).
  14. ncbi Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance
    Christina M Marra
    Department of Neurology, University of Washington School of Medicine, Seattle, USA
    AIDS 23:1359-66. 2009
    To determine whether antiretroviral regimens with good central nervous system (CNS) penetration control HIV in cerebrospinal fluid (CSF) and improve cognition.
  15. ncbi IL-10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infection
    Galit Alter
    Ragon Institute of MGH, MIT, and Harvard, Charlestown, Massachusetts 02129, USA
    J Clin Invest 120:1905-13. 2010
    ..of IL-10 play a central role in progressive immune dysfunction associated with chronic viral infections such as HIV, but the underlying mechanisms are poorly understood...
  16. ncbi Molecular epidemiology of HCV monoinfection and HIV/HCV coinfection in injection drug users in Liuzhou, Southern China
    Yi Tan
    Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong, China
    PLoS ONE 3:e3608. 2008
    Hepatitis C virus (HCV) mono-infection and HCV/HIV (human immunodeficiency virus) co-infection are growing problems in injection drug users (IDU). Their prevalence and genotypic patterns vary with geographic locations...
  17. ncbi Titers of HIV-based vectors encoding shRNAs are reduced by a dicer-dependent mechanism
    Ananthalakshmi Poluri
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mol Ther 16:378-86. 2008
    ..We constructed HIV-based vectors encoding shRNA against HIV coreceptor chemokine (C-C motif) receptor 5 (CCR5)...
  18. ncbi Innate immunity against HIV: a priority target for HIV prevention research
    Persephone Borrow
    Nuffield Department of Clinical Medicine, University of Oxford, The Jenner Institute, Compton, Newbury, Berkshire, UK
    Retrovirology 7:84. 2010
    ..summarizes recent advances and current gaps in understanding of innate immunity to human immunodeficiency virus (HIV) infection, and identifies key scientific priorities to enable application of this knowledge to the development of ..
  19. ncbi Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men
    J T Becker
    University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Neurology 73:1292-9. 2009
    The purpose of this study was to evaluate the relationship between cognitive performance, risk factors for cardiovascular and cerebrovascular disease (CVD), and HIV infection in the era of highly active antiretroviral therapy.
  20. ncbi HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells
    Alyson Yoder
    Department of Molecular and Microbiology, George Mason University, Manassas, VA 20110, USA
    Cell 134:782-92. 2008
    Binding of the HIV envelope to the chemokine coreceptors triggers membrane fusion and signal transduction. The fusion process has been well characterized, yet the role of coreceptor signaling remains elusive...
  21. ncbi Endocytosis of HIV: anything goes
    Marc Permanyer
    Retrovirology Laboratory irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, 08916 Barcelona, Spain
    Trends Microbiol 18:543-51. 2010
    The major pathway for HIV internalization in CD4+ T cells has been thought to be the direct fusion of virus and cell membranes, because the cell surface is the point of entry of infectious particles...
  22. ncbi PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
    Cheryl L Day
    HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu Natal, Durban 4013, South Africa
    Nature 443:350-4. 2006
    ..the role of PD-1 in a chronic human viral infection, we examined PD-1 expression on human immunodeficiency virus (HIV)-specific CD8 T cells in 71 clade-C-infected people who were naive to anti-HIV treatments, using ten major ..
  23. ncbi Improving defences at the portal of HIV entry: mucosal and innate immunity
    Robin J Shattock
    St George's, University of London, London, United Kingdom
    PLoS Med 5:e81. 2008
  24. ncbi Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV
    Erik De Clercq
    Rega Institute for Medical Research, Department of Microbiology and Immunology, Katholieke Universiteit Leuven, Leuven, Belgium
    Int J Antimicrob Agents 33:307-20. 2009
    In 2008, 25 years after the human immunodeficiency virus (HIV) was discovered as the then tentative aetiological agent of acquired immune deficiency syndrome (AIDS), exactly 25 anti-HIV compounds have been formally approved for clinical ..
  25. ncbi Chemokine coreceptor signaling in HIV-1 infection and pathogenesis
    Yuntao Wu
    Department of Molecular and Microbiology, George Mason University, Manassas, Virginia, USA
    PLoS Pathog 5:e1000520. 2009
    Binding of the HIV-1 envelope to its chemokine coreceptors mediates two major biological events: membrane fusion and signaling transduction...
  26. ncbi Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up
    Jens D Lundgren
    Copenhagen HIV Programme CHIP, Faculty of Health Sciences, University of Copenhagen, Panum Institute, 2200 Copenhagen N, Denmark
    J Infect Dis 197:1145-55. 2008
    ..antiretroviral therapy-drug conservation (DC) and viral suppression (VS)-in 5,472 human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts >350 cells/microL...
  27. ncbi HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis
    Virginie Supervie
    Center for Biomedical Modeling, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA
    Proc Natl Acad Sci U S A 107:12381-6. 2010
    The administration of antiretrovirals before HIV exposure to prevent infection (i.e., preexposure prophylaxis; PrEP) is under evaluation in clinical trials...
  28. ncbi Effect of early versus deferred antiretroviral therapy for HIV on survival
    Mari M Kitahata
    University of Washington, Harborview Medical Center, 325 Ninth Ave, Box 359931, Seattle, WA 98104, USA
    N Engl J Med 360:1815-26. 2009
    The optimal time for the initiation of antiretroviral therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection is uncertain.
  29. ncbi High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors
    Claudia Cattoglio
    Istituto Scientifico H San Raffaele, Milan, Italy
    Blood 116:5507-17. 2010
    ..to build genomewide, high-definition maps of > 60 000 integration sites of Moloney murine leukemia virus (MLV)- and HIV-based retroviral vectors in the genome of human CD34(+) multipotent hematopoietic progenitor cells (HPCs) and used ..
  30. ncbi Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype
    Andre Altmann
    Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, Saarbr product operatorcken, Germany
    Antivir Ther 14:273-83. 2009
    ..The utility of an intermediate step of predicting in vitro drug susceptibility is currently controversial. Here, we provide a retrospective comparison of approaches using either genotype or predicted phenotypes alone, or in combination...
  31. ncbi Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level
    Evelien M Bunnik
    Department of Experimental Immunology, Sanquin Research, Landsteiner Laboratory, Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Nat Med 16:995-7. 2010
    By comparing HIV-1 variants from people who became infected at the beginning of the epidemic and from people who have recently contracted the virus, we observed an enhanced resistance of the virus to antibody neutralization over time, ..
  32. ncbi Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities
    Florian Hladik
    Department of Obstetrics and Gynecology, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA
    Antiviral Res 88:S3-9. 2010
    A combination of prevention and treatment modalities will be needed to successfully control the global spread of HIV. Microbicides, drug products topically applied to mucosal surfaces to prevent HIV infection, are one of these biomedical ..
  33. ncbi Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles
    Mayla Hsu
    Aaron Diamond AIDS Research Center and Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 100:7271-6. 2003
    b>HIV pseudotypes bearing native hepatitis C virus (HCV) glycoproteins (strain H and Con1) are infectious for the human hepatoma cell lines Huh-7 and PLC/PR5...
  34. ncbi Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression
    Adam R Hersperger
    Department of Microbiology, University of Pennsylvania, 3610 Hamilton Walk, Philadelphia, PA 19104, USA
    Blood 117:3799-808. 2011
    Recent data suggest that CD8+ T-cell effector activity is an important component in the control of HIV replication in elite controllers (ECs)...
  35. ncbi Innate sensing of HIV-infected cells
    Alice Lepelley
    Institut Pasteur, Virus and Immunity Unit, URA CNRS 3015, Paris, France
    PLoS Pathog 7:e1001284. 2011
    Cell-free HIV-1 virions are poor stimulators of type I interferon (IFN) production. We examined here how HIV-infected cells are recognized by plasmacytoid dendritic cells (pDCs) and by other cells...
  36. ncbi HIV's double strike at the brain: neuronal toxicity and compromised neurogenesis
    Marcus Kaul
    Infectious and Inflammatory Disease Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Front Biosci 13:2484-94. 2008
    Infection with the human immunodeficiency virus-1 (HIV-1) and acquired immunodeficiency syndrome (AIDS) are often associated with severe and debilitating neurological problems that include behavioral abnormalities, motor dysfunction and ..
  37. ncbi Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis
    Yuan Ren
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    J Acquir Immune Defic Syndr 47:566-9. 2008
    ..We evaluated the effect of additional ritonavir on plasma lopinavir concentrations in HIV-infected children receiving rifampicin-based treatment for tuberculosis.
  38. ncbi Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation
    Miguel Stevens
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, B 3000 Leuven, Belgium
    J Antimicrob Chemother 56:847-55. 2005
    Quinolone derivatives have been shown to inhibit human immunodeficiency virus (HIV) replication at the transcriptional level...
  39. ncbi Routine human immunodeficiency virus testing: an economic evaluation of current guidelines
    Rochelle P Walensky
    Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, and the Partners AIDS Research Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Am J Med 118:292-300. 2005
    The Centers for Disease Control and Prevention guidelines recommend human immunodeficiency virus (HIV) counseling, testing, and referral for all patients in hospitals with an HIV prevalence of >or=1%...
  40. ncbi Safety and efficacy of a lentiviral vector containing three anti-HIV genes--CCR5 ribozyme, tat-rev siRNA, and TAR decoy--in SCID-hu mouse-derived T cells
    Joseph Anderson
    Department of Microbiology, Immunology and Pathology, Colorado State University, Fort, Collins, Colorado 80523, USA
    Mol Ther 15:1182-8. 2007
    Gene therapeutic strategies show promise in controlling human immunodeficiency virus (HIV) infection and in restoring immunological function...
  41. ncbi Innate immune recognition and activation during HIV infection
    Trine H Mogensen
    Department of Infectious Diseases, Aarhus University Hospital, Skejby, DK 8200, Aarhus N, Denmark
    Retrovirology 7:54. 2010
    The pathogenesis of HIV infection, and in particular the development of immunodeficiency, remains incompletely understood...
  42. ncbi Pleiotrophin inhibits HIV infection by binding the cell surface-expressed nucleolin
    Elias A Said
    UPR 2228 CNRS, UFR Biomédicale des Saints Pères, Paris, France
    FEBS J 272:4646-59. 2005
    ..reported to bind heparan sulfate and nucleolin, two components of the cell surface implicated in the attachment of HIV-1 particles to cells...
  43. ncbi Timing the emergence of resistance to anti-HIV drugs with large genetic barriers
    Pankhuri Arora
    Department of Chemical Engineering, Indian Institute of Science, Bangalore, India
    PLoS Comput Biol 5:e1000305. 2009
    ..New antiretroviral drugs that offer large genetic barriers to resistance, such as the recently approved inhibitors of HIV-1 protease, tipranavir and darunavir, present promising weapons to avert the failure of current therapies for HIV ..
  44. ncbi HIV integration targeting: a pathway involving Transportin-3 and the nuclear pore protein RanBP2
    Karen E Ocwieja
    Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    PLoS Pathog 7:e1001313. 2011
    Genome-wide siRNA screens have identified host cell factors important for efficient HIV infection, among which are nuclear pore proteins such as RanBP2/Nup358 and the karyopherin Transportin-3/TNPO3...
  45. ncbi Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy
    Tae Wook Chun
    Laboratory of Immunoregulation, National Institutes of Health, Bethesda, MD, USA
    J Infect Dis 204:135-8. 2011
    Residual plasma viremia (<50 copies/mL) persists in certain human immunodeficiency virus (HIV)-infected individuals receiving antiretroviral therapy (ART); however, the relationship between the degree of residual plasma viremia, the ..
  46. ncbi Sequence alignment reveals possible MAPK docking motifs on HIV proteins
    Perry Evans
    Genomics and Computational Biology and Department of Computer and Information Science, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 5:e8942. 2010
    Over the course of HIV infection, virus replication is facilitated by the phosphorylation of HIV proteins by human ERK1 and ERK2 mitogen-activated protein kinases (MAPKs)...
  47. ncbi Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort
    Taisheng Li
    Department of Infectious Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
    PLoS ONE 3:e3918. 2008
    The purpose of this study was to evaluate the efficacy and safety of three nevirapine-based antiretroviral treatments for adult antiretroviral-naïve Chinese patients with HIV-1 infection.
  48. ncbi Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV
    Mark D Hicar
    Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232 2905, USA
    J Acquir Immune Defic Syndr 54:223-35. 2010
    Monomeric HIV envelope vaccines fail to elicit broadly neutralizing antibodies or to protect against infection. Neutralizing antibodies against HIV bind to native functionally active Env trimers on the virion surface...
  49. ncbi Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study
    Max Lataillade
    Global Development and Medical Affairs, Bristol Myers Squibb, Wallingford, Connecticut, USA
    PLoS ONE 5:e10952. 2010
    ..CASTLE compared the efficacy of atazanavir/ritonavir with lopinavir/ritonavir, each in combination with tenofovir-emtricitabine in ARV-naïve subjects from 5 continents...
  50. ncbi Introducing a multi-site program for early diagnosis of HIV infection among HIV-exposed infants in Tanzania
    Harriet Nuwagaba-Biribonwoha
    Columbia University, International Centre for AIDS Care and Treatment Programs ICAP, Dar es Salaam, Tanzania
    BMC Pediatr 10:44. 2010
    In Tanzania, less than a third of HIV infected children estimated to be in need of antiretroviral therapy (ART) are receiving it...
  51. ncbi The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission
    Fatima Nawaz
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 7:e1001301. 2011
    Mucosal transmission of HIV is inefficient. The virus must breach physical barriers before it infects mucosal CD4+ T cells...
  52. ncbi Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing
    Enrico Girardi
    UOC Epidemiologia Clinica, Istituto Nazionale per le Malattie Infettive L Spallanzani IRCCS, Rome, Italy
    J Acquir Immune Defic Syndr 46:S3-8. 2007
    A substantial proportion of HIV-infected individuals do not present for HIV testing until late in infection; these individuals are often ill, have a high mortality risk, and are less likely to respond to treatment when initiated...
  53. ncbi Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction
    Michelle D'Souza
    Department of Medicine, University of Colorado at Denver and Health Sciences Center, Denver, CO 80262, USA
    J Immunol 179:1979-87. 2007
    Functional impairment of HIV-specific CD4(+) T cells during chronic HIV infection is closely linked to viral replication and thought to be due to T cell exhaustion...
  54. ncbi T cell cross-reactivity and conformational changes during TCR engagement
    Jean K Lee
    Human Immunology Unit, Medical Research Council, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, England, UK
    J Exp Med 200:1455-66. 2004
    ..which enables virus escape from immune control by mutation in infections such as the human immunodeficiency virus (HIV)...
  55. ncbi Sexual network structure and the spread of HIV in Africa: evidence from Likoma Island, Malawi
    Stephane Helleringer
    University of Pennsylvania, Population Studies Center, Philadelphia, Pennsylvania 19104, USA
    AIDS 21:2323-32. 2007
    Whereas sexual relationships among low-risk individuals account for the majority of HIV infections in sub-Saharan Africa, limited knowledge exists about the structure and characteristics of sexual networks among the general population in ..
  56. ncbi Mobility of the human immunodeficiency virus (HIV) receptor CD4 and coreceptor CCR5 in living cells: implications for HIV fusion and entry events
    Carolyn M Steffens
    Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, Illinois, USA
    J Virol 78:9573-8. 2004
    ..Interestingly, our findings also suggest that the seven-span transmembrane coreceptor is significantly more mobile than CD4 and requires membrane cholesterol for mobility...
  57. ncbi Tunneling nanotubes (TNT) are induced by HIV-infection of macrophages: a potential mechanism for intercellular HIV trafficking
    E A Eugenin
    Department of Pathology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York, NY 10461, USA
    Cell Immunol 254:142-8. 2009
    ..We demonstrate that HIV-infection of human macrophages results in an increased number of TNT, and show HIV particles within these ..
  58. ncbi 25 years of HIV
    Anthony S Fauci
    National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health in Bethesda, Maryland, USA
    Nature 453:289-90. 2008
  59. ncbi Is HIV becoming more virulent? Initial CD4 cell counts among HIV seroconverters during the course of the HIV epidemic: 1985-2007
    Nancy Crum-Cianflone
    TriService AIDS Clinical Consortium, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Clin Infect Dis 48:1285-92. 2009
    Whether human immunodeficiency virus (HIV) seroconverters have been presenting with progressively lower CD4 cell counts over the course of the HIV epidemic is controversial...
  60. ncbi Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir
    Ahmad R Sedaghat
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Antivir Ther 14:263-71. 2009
    Raltegravir is the first publicly released HIV integrase inhibitor...
  61. ncbi Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells
    Xavier Contreras
    Department of Medicine, University of California, San Francisco, California 94143, USA
    J Biol Chem 284:6782-9. 2009
    Human immunodeficiency virus (HIV) persists in a latent form in infected individuals treated effectively with highly active antiretroviral therapy (HAART)...
  62. ncbi Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety
    Pedro M M Mesquita
    Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    J Infect Dis 200:599-608. 2009
    ..The lack of biomarkers that are predictive of safety is a critical gap in the development of microbicides. The present experiments were designed to evaluate the predictive value of in vitro models of microbicide safety...
  63. ncbi Surveillance for incident HIV infection: new technology and new opportunities
    G W Rutherford
    AIDS Research Institute, San Francisco, California, USA
    J Acquir Immune Defic Syndr 25:S115-9. 2000
    Although surveillance for HIV infection has traditionally focused on the incidence of AIDS and the prevalence of HIV, new diagnostic technologies that allow the estimation of incident HIV infection have become available...
  64. ncbi Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study
    Jason F Okulicz
    Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    J Infect Dis 200:1714-23. 2009
    Durable control of human immunodeficiency virus (HIV) replication and lack of disease progression in the absence of antiretroviral therapy were studied in a military cohort of 4586 subjects...
  65. ncbi Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment
    Brinda Emu
    Department of Medicine, San Francisco General Hospital, University of California, 94110, USA
    J Virol 79:14169-78. 2005
    The human immunodeficiency virus (HIV)-mediated immune response may be beneficial or harmful, depending on the balance between expansion of HIV-specific T cells and the level of generalized immune activation...
  66. ncbi Prevalence and factors involved in discordant responses to highly active antiretroviral treatment in a closely followed cohort of treatment-naïve HIV-infected patients
    Sonia Molina-Pinelo
    Viral Hepatitis and AIDS Study Group, Department of Internal Medicine, , , Seville, Spain
    J Clin Virol 33:110-115. 2005
    ..responses to highly active antiretroviral therapy were analysed in a closely followed cohort of 51 naïve HIV-infected patients at 48 weeks...
  67. ncbi Recovery of CD4+ T Cells in HIV patients with a stable virologic response to antiretroviral therapy is associated with polymorphisms of interleukin-6 and central major histocompatibility complex genes
    Sonia Fernandez
    Clinical Immunology and Biochemical Genetics, Royal Perth Hospital, Perth, Western Australia, Australia
    J Acquir Immune Defic Syndr 41:1-5. 2006
    We investigated whether polymorphisms in genes associated with HIV disease progression and/or immune activation affect CD4+ T-cell recovery in HIV patients who began combination antiretroviral therapy (ART) with advanced immunodeficiency ..
  68. ncbi Antiretroviral treatment strategies and immune reconstitution in treatment-naïve HIV-infected patients with advanced disease
    Alessandro Soria
    Clinic of Infections Disease, San Raffaele Scientific Institute, Milan, Italy
    J Acquir Immune Defic Syndr 46:S19-30. 2007
    Treatment-naïve advanced HIV-infected patients have a lower life expectancy than those treated early with highly active antiretroviral therapy (HAART)...
  69. ncbi Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine
    Diane V Havlir
    Department of Medicine, San Francisco General Hospital, University of California at San Francisco, San Francisco, California, USA
    J Infect Dis 191:1164-8. 2005
    In human immunodeficiency virus (HIV)-infected patients successfully treated with highly active antiretroviral therapy (HAART), a low level of HIV RNA persists in plasma at steady state for years and varies among patients...
  70. ncbi [HIV-infection: modern antiretroviral therapy]
    J K Rockstroh
    ,
    Dtsch Med Wochenschr 129:1921-4. 2004
  71. ncbi The challenge of antiretroviral-drug-resistant HIV: is there any possible clinical advantage?
    Mauro Zaccarelli
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    Curr HIV Res 2:283-92. 2004
    ..Despite the main goal of antiretroviral therapy should be achievement of complete suppression of HIV replication, the accumulation of resistance mutations in patients with multiple treatment failure makes this ..
  72. ncbi Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy
    Colette J Smith
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, United Kingdom
    J Infect Dis 190:1860-8. 2004
    ..We sought to investigate the factors associated with increases in CD4 cell count among human immunodeficiency virus (HIV)-positive antiretroviral-naive patients starting HAART.
  73. ncbi Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy
    L Sarmati
    Department of Public Health, University of Rome Tor Vergata, Rome, Italy
    J Med Virol 72:511-6. 2004
    A longitudinal study of the replication capacity of HIV strains isolated from 18 patients failing highly active antiretroviral therapy (HAART) was undertaken at the time of genotypic guided change of therapy and after 12 months...
  74. ncbi Understanding the role of HIV load in determining weight change in the era of highly active antiretroviral therapy
    D Mkaya Mwamburi
    Division of Geographic Medicine and Infectious Diseases, Tufts New England Medical Center, Boston, MA 02111, USA
    Clin Infect Dis 40:167-73. 2005
    In this prospective cohort study, we determined the relationship between human immunodeficiency virus (HIV) RNA load and body weight in patients with HIV infection.
  75. ncbi Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors
    Honghu Liu
    Division of General Internal Medicine and Health Services Research, Department of Medicine, University of California Los Angeles UCLA, 911 Broxton Plaza, Los Angeles, CA 90095 1736, USA
    J Acquir Immune Defic Syndr 41:315-22. 2006
    Adherence to antiretroviral medications is critical to achieving HIV viral suppression...
  76. ncbi HIV therapy after treatment interruption in patients with multiple failure and more than 200 CD4+ T lymphocyte count
    Acil Jaafar
    Laboratoire de Virologie, , CHU Toulouse, , France
    J Med Virol 74:8-15. 2004
    ..Patients were tested for HIV resistance before and after treatment interruption...
  77. ncbi Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infection
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 9:139-42. 2004
  78. ncbi Differences in nocturnal basal and rhythmic prolactin secretion in untreated compared to treated HIV-infected men are associated with CD4+ T-lymphocytes
    Adalberto Parra
    Department of Endocrinology, Instituto Nacional de Perinatologia, Mexico City, Mexico
    Immunol Cell Biol 82:24-31. 2004
    The existence of decreased hypothalamic dopaminergic tone in HIV-infected men has been suggested...
  79. ncbi Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART
    Emanuele Nicastri
    National Institute of Infectious Diseases, IRCCS L. Spallanzani, Rome, Italy
    J Med Virol 76:153-60. 2005
    ..027 and P = 0.035, respectively). Using politomous analysis, patients baseline HIV-RNA level more than 5 log cp/ml had a 1...
  80. ncbi A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries
    Robert Colebunders
    Infectious Disease Institute, Faculty of Medicine, Makerere University, Kampala, Uganda
    Lancet Infect Dis 6:53-9. 2006
    ..Not only that, but most HIV patients in resource-poor countries do not have access to such testing...
  81. ncbi Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCV-coinfected patients according to the pattern of response to highly active antiretroviral therapy
    Mariacarmela Solmone
    National Institute of Infectious Diseases L Spallanzani, Rome
    Antivir Ther 11:87-94. 2006
    ..This study was aimed at studying the changes in HVR-1 heterogeneity and the evolution of HCV quasispecies in HIV/HCV-coinfected patients according to the pattern of response to highly active antiretroviral therapy (HAART)...
  82. ncbi Decreasing CD4+ T-cell count during suppressed or low-level viraemia in patients with HIV infection
    Albert M L Anderson
    Department of Medicine, Division of Infectious Diseases, Duke University Medical Centre, Durham, NC, USA
    Antivir Ther 12:1041-8. 2007
    Suboptimal improvement in CD4+ T-cell count is not uncommon in HIV-infected patients with suppressed plasma HIV RNA levels, and a decrease in CD4+ T-cell count in patients with suppressed or low-level viraemia has been observed.
  83. ncbi Do CD8(+)CD25(+) cells predict immune reconstitution syndrome in HIV-positive patients who begin HAART?
    Malena Cianchetta-Sivori
    Department of Immunology, Fundacion Jimenez Diaz Capio, Madrid, Spain
    AIDS 21:2347-9. 2007
    ..We found that CD8(+)CD25(+) cell pretreatment values in patients who developed IRS were four times higher than in those patients who did not develop IRS...
  84. ncbi Current status of HIV infection: a review for non-HIV-treating physicians
    Bettina Knoll
    Department of Medicine, Mayo Clinic College of Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Int J Dermatol 46:1219-28. 2007
    An estimated 40 million people live with human immunodeficiency virus (HIV) globally, and over four million people were newly diagnosed with HIV infection in 2006...
  85. ncbi Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir
    Sandra M J De Meyer
    Clinical Virology Department, Tibotec BVBA, Generaal De Wittelaan L11 B3, Mechelen, Belgium
    J Acquir Immune Defic Syndr 49:179-82. 2008
    ..objective of this study was to examine the potential of once-daily dosing with darunavir/ritonavir 800/100 mg in a HIV-infected, treatment-experienced patient population with no baseline darunavir resistance-associated mutations (RAMs)...
  86. ncbi Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations
    Jesse D Raffa
    J Acquir Immune Defic Syndr 47:397-9. 2008
  87. ncbi Mutation and control of the human immunodeficiency virus
    Robert F Stengel
    Department of Mechanical and Aerospace Engineering, Princeton University Princeton, P O Box CN5263, Princeton, NJ 08544 5263, USA
    Math Biosci 213:93-102. 2008
    We examine the dynamics of infection by the human immunodeficiency virus (HIV), as well as therapies that minimize viral load, restore adaptive immunity, and use minimal dosage of anti-HIV drugs...
  88. ncbi Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe
    Sylvia K Muyingo
    MRC Uganda Research Unit on AIDS, Entebbe, Uganda
    J Acquir Immune Defic Syndr 48:468-75. 2008
    ..Good adherence is essential for successful antiretroviral therapy (ART) provision, but simple measures have rarely been validated in Africa...
  89. ncbi Short- and long-term efficacy of modified directly observed antiretroviral treatment in Mombasa, Kenya: a randomized trial
    Avina Sarna
    Population Council, New Delhi, India
    J Acquir Immune Defic Syndr 48:611-9. 2008
    ..To determine short- and long-term efficacy of modified directly observed therapy (m-DOT) on antiretroviral adherence...
  90. ncbi Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon
    Barbara H McGovern
    Lemuel Shattuck Hospital, Jamaica Plain, MA 02130, USA
    Clin Infect Dis 45:1386-92. 2007
    Human immunodeficiency virus (HIV)-infected patients with hepatitis C virus (HCV) coinfection are at increased risk for drug-induced liver injury (DILI) compared with patients with HIV infection alone...
  91. ncbi Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children
    Carina A Rodriguez
    Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, University of South Florida, College of Medicine, All Children s Hospital, St Petersburg, FL 33701 4899, USA
    Immunol Res 40:271-86. 2008
    Many HIV-infected children treated with protease inhibitors (PI) reconstitute immunity despite viral breakthrough predicting disease progression...
  92. ncbi Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they mean?
    Katherine J Lee
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 12:949-56. 2007
    To investigate transient increases in viral load during sustained suppression in children in the UK and Ireland Collaborative HIV Paediatric Study (CHIPS).
  93. ncbi Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study
    Nicola Gianotti
    Clinica di Malattie Infettive, Universita Vita Salute San Raffaele, Milan, Italy
    Clin Infect Dis 42:1470-80. 2006
    There is still considerable uncertainty as to the best algorithm for interpreting human immunodeficiency virus (HIV) genotyping results.
  94. ncbi Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients
    Dianne Langford
    Department of Pathology, University of California, San Diego, La Jolla, California 92093, USA
    J Neurovirol 12:100-7. 2006
    Human immunodeficiency virus (HIV)-1 invades the central nervous system (CNS) soon after infection and is partially protected there from host immunity and antiretroviral drugs (ARVs)...
  95. ncbi Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring
    Xiuhong Li
    Room E7648, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    J Epidemiol Community Health 60:811-8. 2006
    STUDY OBJECTIVE: To assess whether HIV RNA levels (log(10) scale) in highly active antiretroviral therapy (HAART) treated population have a bimodal distribution, suggesting optimal or suboptimal response to HAART...
  96. ncbi Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more
    MaMercedes Nogueras
    Infectious Diseases Program, Corporacio Sanitaria Parc Tauli, Sabadell, Barcelona, Spain
    BMC Infect Dis 6:159. 2006
    Over the last years, the mean age of subjects with HIV infection and AIDS is increasing. Moreover, some epidemiological and clinical differences between younger and older HIV-infected individuals have been observed...
  97. ncbi Predictors of immunity after hepatitis A vaccination in HIV-infected persons
    E T Overton
    Washington University School of Medicine, St Louis, MO, USA
    J Viral Hepat 14:189-93. 2007
    Hepatitis A virus (HAV) infection remains a health risk for human immunodeficiency virus (HIV)-infected persons...
  98. ncbi [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005]
    M Oette
    Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Universitatsklinikum Dusseldorf
    Dtsch Med Wochenschr 132:977-82. 2007
    Primary HIV drug resistance, characterized by mutant virus strains in untreated HIV-infected persons, is of significant epidemiological significance. Primary resistance is associated with reduced efficacy of antiretroviral therapy (ART)...
  99. ncbi CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003
    W Stöhr
    MRC Clinical Trials Unit, London, UK
    HIV Med 8:135-41. 2007
    ..We examined whether the timing of initiation of antiretroviral therapy (ART) in routine clinical practice reflected treatment guidelines, which have evolved towards recommending starting therapy at lower CD4 cell counts...
  100. ncbi Natural history of compensated and decompensated HCV-related cirrhosis in HIV-infected patients: a prospective multicentre study
    José A Girón-González
    Infectious Diseases Unit, Internal Medicine Service, Hospital Universitario Puerta del Mar, Cadiz, Spain
    Antivir Ther 12:899-907. 2007
    To define the course of HIV-HCV-coinfected patients with compensated and decompensated liver cirrhosis and to investigate the survival and the risk factors for death.
  101. ncbi Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases
    Jason V Baker
    Department of Biostatistics, University of Minnesota, Minneapolis, MN, USA
    J Acquir Immune Defic Syndr 48:541-6. 2008
    ..Low CD4+ increases risk for both AIDS- and non-AIDS-related morbidity and mortality. The magnitude of CD4+ recovery early after initial antiretroviral therapy (ART) is important in the ultimate duration of immune depletion...

Research Grants87

  1. Relationship of metabolic abnormalities to hepatic steatosis in HIV
    Richard Sterling; Fiscal Year: 2007
    Abnormal liver enzymes are frequently seen in those with HIV. Although many of these individuals are co-infected with HBV or HCV, histology in HIV patients with abnormal liver enzymes in the absence of viral hepatitis has not been ..
  2. Role of the OPI1 gene in controlling viability of Candida glabrata
    TODD REYNOLDS; Fiscal Year: 2007
    ..However, as the population of patients treated by HAART ages, the needs of elderly Human Immunodeficiency Virus (HIV) positive patients will become a very important concern because immune function will decline...
  3. Vaccination against mucosal HIV clade C transmission
    Ruth Ruprecht; Fiscal Year: 2007
    Most HIV transmissions occur mucosally, including mother-to-child transmission (MTCT). As HIV clade C predominates worldwide, we initially focused on immunoprevention of HIV clade C MTCT...
  4. Evaluation of RNA transport elements in HIV-1 vectors
    SRINIVAS KUMAR; Fiscal Year: 2007
    ..In the case of human immunodeficiency virus (HIV), the viral Rev protein, in conjunction with an RNA element (Rev-response element or RRE), has been shown to assist ..
  5. Infant immunoprophylaxis against a primate lentivirus
    Ruth Ruprecht; Fiscal Year: 2007
    Our long-term goal is to develop passive immunization against maternal HIV transmission during birth and through breast milk...
  6. International HIV-associated Opportunistic Pneumonias (IHOP) Study
    Laurence Huang; Fiscal Year: 2009
    ..opportunistic pneumonias have been major causes of morbidity and mortality among human immunodeficiency virus (HIV)-infected persons...
  7. International HIV-associated Opportunistic Pneumonias (IHOP) Study
    Laurence Huang; Fiscal Year: 2009
    ..opportunistic pneumonias have been major causes of morbidity and mortality among human immunodeficiency virus (HIV)-infected persons...
  8. Genome Integrity in Candida albicans
    Judith G Berman; Fiscal Year: 2010
    ..candidiasis is often the earliest detectable clinical manifestation of infection with Human Immunodeficiency Virus (HIV) and the most prevalent opportunistic infection observed in patients with Acquired Immunodeficiency Syndrome (AIDS)...
  9. Haemophilus ducreyi Resistance to Antimicrobial Peptides
    MARGARET BAUER; Fiscal Year: 2007
    ..transmitted genital ulcer disease that facilitates transmission and acquisition of human immunodeficiency virus (HIV) and thus contributes to the spread of HIV in areas with endemic chancroid. H...
  10. MUCOSAL DEFENSE MECHANISMS IN SUBSTANCE ABUSE
    David Brown; Fiscal Year: 2009
    ..at mucosal immune sites by detecting and eliminating enteric pathogens, including the human immunodeficiency virus (HIV) and Salmonella enterica...
  11. MUCOSAL DEFENSE MECHANISMS IN SUBSTANCE ABUSE
    David R Brown; Fiscal Year: 2010
    ..at mucosal immune sites by detecting and eliminating enteric pathogens, including the human immunodeficiency virus (HIV) and Salmonella enterica...
  12. Effect of Cdk inhibitor on HIV-1 replication
    Fatah Kashanchi; Fiscal Year: 2007
    There are currently 40-100 million individuals in the world infected with human immunodeficiency virus (HIV), and nearly 16,000 new infections occur worldwide each day based on World Health Organization estimates...
  13. Positron Emission Tomography to Evaluate Thymic Function
    Laura Napolitano; Fiscal Year: 2006
    Acquired immunodeficiencies, such as those caused by human immunodeficiency virus (HIV)-1 infection, are frequently characterized by T cell loss and an increased risk of illness or death from infection...
  14. NUCLEOSIDES WITH DUAL ANTI-HIV AND HBV ACTIVITY
    RAYMOND SCHINAZI; Fiscal Year: 2007
    ..The search for new therapies against human immunodeficiency virus (HIV), led to the discovery that certain 2',3'- didehydro-2',3'-dideoxynucleosides (d4N) and their 2'-fluoro analogs are ..
  15. Methamphetamine, HIV, Neuroinflammation and Behavior
    Rodney Johnson; Fiscal Year: 2007
    ..is associated with increased frequency of high-risk sexual behavior leading to human immunodeficiency virus type 1 (HIV-1) exposure...
  16. Epigenetic regulation of HIV latency
    ERIC M VERDIN; Fiscal Year: 2010
    ABSTRACT The presence of latent reservoirs has prevented the eradication of Human Immunodeficiency Virus (HIV) from infected patients successfully treated with antiretroviral therapy...
  17. Virologic and Immunologic Studies of Murine CMV Retinitis
    Sally Atherton; Fiscal Year: 2009
    The incidence of cytomegalovirus retinitis has decreased in human immunodeficiency virus (HIV)-infected patients concomitant with the widespread use of highly actively antiretroviral therapy (HAART)...
  18. Virologic and Immunologic Studies of Murine CMV Retinitis
    Sally S Atherton; Fiscal Year: 2010
    The incidence of cytomegalovirus retinitis has decreased in human immunodeficiency virus (HIV)-infected patients concomitant with the widespread use of highly actively antiretroviral therapy (HAART)...
  19. Establishment fo HIV infection in cotton rats
    Jorge Blanco; Fiscal Year: 2007
    The development of a small animal model to study human immunodeficiency virus type-1 (HIV-1) infection would significantly facilitate studies of disease pathogenesis, as well as vaccine and anti-viral drug development and testing...
  20. HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE
    Ben Dunn; Fiscal Year: 1993
    ..is to examine the biochemical consequences of the wide genetic diversity in the sequence of the proteolytic enzyme, HIV PR...
  21. Role of Cellular Factors in Retroviral Uncoating and Synthesis of Viral DNA
    Felipe Diaz Griffero; Fiscal Year: 2010
    Early steps in human immunodeficiency virus (HIV-1) replication involve delivery of the viral core into the cytoplasm of the host cell. When the viral core has reached the cytoplasm a process known as "uncoating" takes place...
  22. Structure-based discovery and development of HIV-1 gp41 fusion inhibitors
    Miriam Gochin; Fiscal Year: 2010
    ..discovery and development of low molecular weight gp41 inhibitors effective against Human Immunodeficiency Virus (HIV-1) fusion...